Article Sidebar
Article Details
Copyright remains in the Author’s name. The work is licensed under a Creative Commons Attribution - Noncommercial Works License. Authors are required to complete and sign an Author Agreement form that outlines Author and Publisher rights and terms of publication. The Agreement form should be uploaded along with other submissions files and any submission will be considered incomplete without it [forthcoming].
Material submitted for publication in the SAMJ is accepted provided it has not been published or submitted for publication elsewhere. Please inform the editorial team if the main findings of your paper have been presented at a conference and published in abstract form, to avoid copyright infringement. The SAMJ does not hold itself responsible for statements made by the authors.
Previously published images
If an image/figure has been previously published, permission to reproduce or alter it must be obtained by the authors from the original publisher and the figure legend must give full credit to the original source. This credit should be accompanied by a letter indicating that permission to reproduce the image has been granted to the author/s. This letter should be uploaded as a supplementary file during submission.
Main Article Content
The effects of buserelin microparticles on ovarian function in healthy women
Abstract
Objective. To investigate the tolerance, pharmacokinetics and pharmacodynamJcs of the microparticle fonnulation of buserelin, when it wasaaministered subcutaneously.
Design. A single-blind, randomised, parallel-group design was used to investigate the duration of suppression of ovarian function associated with doses of 1,8, 3,6 and 7,2 mg buserelin administered subcutaneously as microparticles.
Setting. The study was carried out at the Hoechst Research Centre for Clinical Pharmacology, Department of Pharmacology, University of the Orange Free State, Bloemfontein.
Patients. Thirty-two healthy premenopausal female volunteers aged between 19 and 39 years and weighing between 52 and 85 kg completed the study.
Outcome measures. Serum progesterone and oestradiol concentrations were measured twice weekly until normal ovarian function resumed, i.e. when serum progesterone concentrations increased to at least 8 nmoVI (a sign of ovulation) and oestradiol concentrations increased to values above 300 pmol/l. Serum and urinary concentrations of buserelin were measured at the same times as those of progesterone and oestradiol.
Results. Doses of 1,8,3,6 and 7,2 mg elicited anovulation for mean periods of 52, 77 and 113 days and suppressed ovarian production of oestrogen for 19, 38 and 69 days. Resumption of normal ovarian function occurred when serum buserelin concentrations decreased to between 0,03 and 0,05 lJg/ml. The correlation coefficient between dose and duration of anovulation was 0,75; the correlation coefficient between dose and duration of suppression of oestrogen production was 0,76.
Conclusion. Apart from minor side-effects such as hot flushes, vaginal spotting and acne, the compound was tolerated well. We conclude that a good relationship exists between dose and duration of suppression of ovarian function. Doses of 3,6 - 7,2 mg buserelin should suppress oestrogen production for approximately 6 - 9 weeks and ovulation for 11 - 16 weeks.
